FDA panel: Don't compound Vioxx, Bextra, oxy-ER
This article was originally published in Scrip
Executive Summary
A decade after Merck yanked Vioxx and Pfizer withdrew Bextra from the market because of cardiovascular concerns associated with the anti-inflammatory drugs, an FDA panel of outside experts on 23 February said those drugs' active ingredients – rofecoxib and valdecoxib, respectively – should not be compounded by US pharmacists.